{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T11:35:38Z","timestamp":1782646538027,"version":"3.54.5"},"reference-count":25,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14542","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:42:06Z","timestamp":1719571326000},"source":"Crossref","is-referenced-by-count":1,"title":["Irinotecan plus raltitrexed as second\u2011line chemotherapy for metastatic colorectal cancer: A retrospective study"],"prefix":"10.3892","volume":"28","author":[{"given":"Jie","family":"Lian","sequence":"first","affiliation":[{"name":"Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"key20240805083121_b1-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20240805083121_b2-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1186\/s12889-019-7318-8","article-title":"The impact of screening on the survival of colorectal cancer in Shanghai, China: A population based study","volume":"19","author":"Li","year":"2019","journal-title":"BMC Public Health"},{"key":"key20240805083121_b3-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdt479","article-title":"Final results of Australasian gastrointestinal trials group ARCTIC study: An audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines","volume":"25","author":"Ransom","year":"2014","journal-title":"Ann Oncol"},{"key":"key20240805083121_b4-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/CAD.0000000000000133","article-title":"A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer","volume":"25","author":"Barni","year":"2014","journal-title":"Anticancer Drugs"},{"key":"key20240805083121_b5-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.clcc.2020.09.006","article-title":"Real-world safety and efficacy of raltitrexed in patients with metastatic colorectal cancer","volume":"20","author":"Batra","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"key20240805083121_b6-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/annonc\/mdg285","article-title":"Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer","volume":"14","author":"Aparicio","year":"2003","journal-title":"Ann Oncol"},{"key":"key20240805083121_b7-ol-28-3-14542","first-page":"1391","article-title":"Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer","volume":"25","author":"Chiara","year":"2005","journal-title":"Anticancer Res"},{"key":"key20240805083121_b8-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000065719","article-title":"Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer","volume":"63","author":"Aparicio","year":"2002","journal-title":"Oncology"},{"key":"key20240805083121_b9-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"RECIST 1.1-standardisation and disease-specific adaptations: Perspectives from the RECIST working group","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20240805083121_b10-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"JCO2018788620","DOI":"10.1200\/JCO.2018.78.8620","article-title":"Feasibility of implementing the patient-reported outcomes version of the common terminology criteria for adverse events in a multicenter trial: NCCTG N1048","volume":"36","author":"Basch","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20240805083121_b11-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"e0116774","DOI":"10.1371\/journal.pone.0116774","article-title":"Statistical inference methods for two crossing survival curves: A comparison of methods","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"key20240805083121_b12-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"302","DOI":"10.21147\/j.issn.1000-9604.2021.03.02","article-title":"Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020","volume":"33","author":"Dong","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"key20240805083121_b13-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/ph14070639","article-title":"Anticancer drugs for intra-arterial treatment of colorectal cancer liver metastases: In-vitro screening after short exposure time","volume":"14","author":"Fohlen","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20240805083121_b14-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.dld.2021.08.009","article-title":"First-line chemotherapy with raltitrexed in metastatic colorectal cancer: An association des gastro-ent\u00e9rologues oncologues (AGEO) multicentre study","volume":"54","author":"Gallois","year":"2022","journal-title":"Dig Liver Dis"},{"key":"key20240805083121_b15-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.ejca.2011.04.024","article-title":"Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]","volume":"47","author":"Clarke","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20240805083121_b16-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.clcc.2013.09.001","article-title":"Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: A randomized phase II study","volume":"12","author":"Bendell","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"key20240805083121_b17-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"10732748221080332","DOI":"10.1177\/10732748221080332","article-title":"Biweekly raltitrexed combined with irinotecan as second-line therapy for patients with metastatic colorectal cancer: A phase II trial","volume":"29","author":"Cheng","year":"2022","journal-title":"Cancer Control"},{"key":"key20240805083121_b18-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1002\/cam4.3940","article-title":"Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients","volume":"10","author":"Arhin","year":"2021","journal-title":"Cancer Med"},{"key":"key20240805083121_b19-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12029-016-9895-4","article-title":"Surgical management of metastatic colorectal cancer: A single-centre experience on oncological outcomes of pulmonary resection vs cytoreductive surgery and HIPEC","volume":"48","author":"Wong","year":"2017","journal-title":"J Gastrointest Cancer"},{"key":"key20240805083121_b20-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2017.03.007","article-title":"Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial","volume":"78","author":"Yoshino","year":"2017","journal-title":"Eur J Cancer"},{"key":"key20240805083121_b21-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1007\/s00330-018-5967-0","article-title":"Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer","volume":"29","author":"Palmieri","year":"2019","journal-title":"Eur Radiol"},{"key":"key20240805083121_b22-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3390\/cancers13153863","article-title":"Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience","volume":"13","author":"Lavacchi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20240805083121_b23-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamaoncol.2018.4465","article-title":"Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: The UNICANCER PRODIGE18 randomized clinical trial","volume":"5","author":"Bennouna","year":"2019","journal-title":"JAMA Oncol"},{"key":"key20240805083121_b24-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s10147-015-0911-7","article-title":"Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (the ORION study)","volume":"21","author":"Matsuda","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"key20240805083121_b25-ol-28-3-14542","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1634\/theoncologist.2012-0071","article-title":"A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)","volume":"17","author":"Hurwitz","year":"2012","journal-title":"Oncologist"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:31:28Z","timestamp":1722835888000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6,28]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14542","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"article-number":"409"}}